Abstract
Brain metastases are the most common intracranial tumors, with an incidence rate ranging from 7 to 14 per 100,000. Both the disease process itself and its treatments can be associated with debilitating and life-altering neurocognitive adverse effects. The treatment of brain metastases involves a multidisciplinary team that aims to maximize the benefits and minimize the toxicities of treatment, which may include surgical resection, radiation therapy (stereotactic radiosurgery or whole-brain radiation therapy), and/or systemic therapy. Additionally, strategies have been investigated to prevent and treat these toxicities, such as stereotactic radiosurgery, hippocampal avoidance whole-brain radiation therapy, and “neuroprotective” drugs, respectively. In order to better detect and measure treatment toxicity, efforts have also been deployed in tracking neurocognitive changes consistently in patients with brain metastases.
| Original language | English (US) |
|---|---|
| Title of host publication | Central Nervous System Metastases |
| Publisher | Springer International Publishing |
| Pages | 315-328 |
| Number of pages | 14 |
| ISBN (Electronic) | 9783030234171 |
| ISBN (Print) | 9783030234164 |
| DOIs | |
| State | Published - Jan 1 2019 |
Keywords
- Brain metastasis
- Clinical outcome assessment
- Hippocampal avoidance whole-brain radiation therapy
- Memory
- Neurocognitive function
- Neuropsychological testing
- Radiation
- Stereotactic radiosurgery
- Systemic therapy
ASJC Scopus subject areas
- General Medicine
- General Social Sciences